Pharmacokinetic comparisons of S-oxiracetam and R-oxiracetam in beagle dogs
By: Wusan Wang, Hui Ji, Tingting Li, Yuanwei Jia and Haitang Xie
References
- 1. Z. Hlinak, J. Vinsova and E. Kasafirek, Effect of alaptide, its analogues and oxiracetam on memory for an elevated plus-maze in mice,(1996) 1–7.
- 2. Z. Hlinak and I. Krejci, Oxiracetam pre-but not post-treatment prevented social recognition deficits produced with trimethyltin in rats,(2005) 213–219; DOI: 10.1016/j.bbr.2005.02.030.
- 3. C. Mondadori, B. Hengerer, T. Ducret and J. Borkowski, Delayed emergence of effects of memoryenhancing drugs: implications for the dynamics of long-term memory,(1994) 2041–2045.
- 4. C. Mondadori, H. J. Möbius and J. Borkowski, The GABAB receptor antagonist CGP 36,742 and the nootropic oxiracetam facilitate the formation of long-term memory,.(1996) 223–225.
- 5. W. H. Brooks, W. C. Guida and K. G. Daniel, The significance of chirality in drug design and development,.(2011) 760–770; DOI: 10.2174/156802611795165098.
- 6. A. J. Hutt, Chirality and pharmacokinetics: an area of neglected dimensionality,.(2007) 79–112; DOI: 10.1515/DMDI.2007.22.2-3.79.
- 7. T. Kolev, M. Spiteller and B. Koleva, Spectroscopic and structural elucidation of amino acid derivatives and small peptides: experimental and theoretical tools,(2010) 45–50; DOI: 10.1007/s00726-008-0220-9.
- 8. H. Lu, Stereoselectivity in drug metabolism,.(2007) 149–158; DOI: 10.1517/17425255.3.2.149.
- 9. Q. Shen, L. Wang, H. Zhou, L. S. Yu and S. Zeng, Stereoselective binding of chiral drugs to plasma proteins,(2013) 998–1006; DOI: 10.1038/aps.2013.78.
- 10. N. Inotsume and M. Nakano, Stereoselective determination and pharmaco-kinetics of dihydropyridines: an updated review,(2002) 255–274; DOI: 10.1016/S0165-022X(02)00120-3.
- 11. R. Mehvar and D. R. Brocks, Stereospecific pharmacokinetics and pharmacodynamics of betaadrenergic blockers in humans,.(2001) 185–200.
- 12. L.A. Nguyen, H. He and C. Pham-Huy, Chiral drugs: an overview,(2006) 85–100.
- 13. L. Chiodini, G. Pepeu,, EP. WO 1,993,006,826 A1, 15 April 1993; ref.119 (1993) 139083.
- 14. W. S. Wang, H. Ji, H. T. Xie, M. Dai, Y. W. Jia, D. H. Liang, L. Ye and Z. Y. Rong, A sensitive and specific UPLC–MS/MS analysis and preliminary pharmacokinetic characterization of S-oxiracetam in beagle dogs,.(2012) 988–994.
- 15. J. B. Lecaillon, J. P. Dubois, H. Coppens, T. Darragon, W. Theobald, G. Reumond and H. Beck, Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with nongeriatric healthy subjects,(1990) 223–237.
- 16. E. Perucca, A. Albrici, G. Gatti, R. Spalluto, M. Visconti and A. Crema, Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers,.(1984) 267–274.
- 17. E. Perucca, J. Parini, A. Albrici, M. Visconti and E. Ferrero, Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly,(1987) 145148.
- 18. X. Wan, H. Wang, P. Ma, L. Xi, J. Sun, Z. He, X. Zhang and X. Liu, Simultaneous determination of oxiracetam and its degraded substance in rat plasma by HPLC–MS/MS and its application to pharmacokinetic study after a single high-dose intravenous administration,.(2014) 95–100; DOI: 10.1016/j.jchromb.2014.07.041.
Language: English
Page range: 279 - 287
Accepted on: Oct 27, 2015
Published on: May 28, 2016
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2016 Wusan Wang, Hui Ji, Tingting Li, Yuanwei Jia, Haitang Xie, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.